Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
Predicting response to peginterferon α-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B
复制标题
DOI：
10.1136/gut.2005.089722
复制
发表时间：
2007-05-01
期刊：
影响因子：
24.5
通讯作者：
McCloud, P.
中科院分区：
文献类型：
--
作者：
Bonino, F.;Marcellin, P.;McCloud, P.
目的：在一项针对B e抗原（HBeAg）阴性慢性B型肝炎患者的试验中，聚乙二醇干扰素α-2a联合或不联合拉米夫定治疗24周后的生化学和病毒学应答率显著高于单用拉米夫定。治疗前因素对治疗后responses.Methods的影响：多变量分析进行了使用现有的数据从518例患者与聚乙二醇干扰素α-2a治疗或不与拉米夫定，或与拉米夫定单独。治疗后反应定义为丙氨酸氨基转移酶（ALT）正常化和乙型肝炎病毒（B）DNA水平
Objective: In a trial of patients with hepatitis B e antigen (HBeAg)-negative chronic hepatitis B, 24 week post-treatment biochemical and virological response rates with peginterferon alpha-2a with or without lamivudine were significantly higher than with lamivudine alone. The effect of pre-treatment factors on post-treatment responses was investigated.Methods: Multivariate analyses were performed using available data from 518 patients treated with peginterferon alpha-2a with or without lamivudine, or with lamivudine alone. A post-treatment response was defined as alanine aminotransferase (ALT) normalisation and hepatitis B virus (HBV) DNA level of